Answers are grounded in this paper and cite their sources.
Background Patients with Turner syndrome have a distinct pattern of neoplastic events occurrence, although their overall cancer risk does not appear to exceed that of the general population. Recombinant human growth hormone (rhGH) therapy is widely used to improve adult height, but concerns remain regarding its long-term safety. Objective To evaluate the long-term risk of neoplastic events among patients with Turner syndrome treated with rhGH during childhood and to examine associations between rhGH treatment duration or dose. Design, Setting and Participants Nationwide population-based cohort study including all Swedish patients with Turner syndrome treated with rhGH during childhood between 1983 and 2010 (n=583) and matched comparators (n=8745). Follow-up continued until the first neoplastic event, death, emigration or December 31, 2020. Results During a mean follow-up of 20.2 years (188445 person-years), patients with Turner syndrome had an increased hazard of overall neoplastic events (Hazard Ratio, HR, 2.0, 95% confidence interval, CI: 1.7-2.4), and of benign neoplasms (HR 2.5, 95% CI: 2.1-3.0), but not of malignant neoplasms (HR 0.7, 95% CI: 0.5-1.1). Hazards were increased for malignant neoplasms of the gastrointestinal tract and several benign neoplasms, while female genital malignancies were decreased. Neither rhGH treatment duration nor dose was associated with malignant or overall neoplastic risk. Conclusion and Relevance Patients with Turner syndrome treated with rhGH in childhood had an increased risk of overall neoplastic events driven primarily by benign neoplasms. No association was observed between rhGH treatment duration or dose and neoplastic risk in early to mid-adulthood, supporting its long-term safety.
No takes yet. Share an insight, caveat, or question.
Aeppli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: